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;' ACCELERATED and hyperacute rejections in presen-
. . sitized transplant patients constitute major causes of 
-:: early allograft loss. Analysis of the distinct role of various 
:~, transplantation antigens in the process of sensitization is 
therefore important in further understanding and subse-
.... ~-quently preventing the occurrence of such events. The 
:.~. recent availability of Hknock out"' mice. which do not 
~. express major histocompatibility complex (MHC) class I or 
':<cIass II molecules. 1.1 has provided a tool to analyze the role 
:;" Of these antigens in the initiation of immune responses to 
';<- allosensitization. In this study. we have presensitized mice 
.).. 
" with skin grafts from either class I or class II MHC-deficient 
donors, and then examined the sensitization status of the 
.,. recipients by subsequent heart or liver grafting. The cellular 
ii and humoral immune responses of the sensitized recipients 
'~.r 
, :-~::::d~ETHODS 
.,. Animals and Surgical Procedures 
> Male 10- to 12-week-old inbred C57BUI0 (BIO. H-:!'). C57BU6 
;., (86, H-:!'), BIO.BR (H-2"). C3H (H-2"l. b2m (H-:!'. class I 
<)I.. 
deficient). and BALB/c (H-?) mice were purchased from the 
Jackson Laboratory (Bar Harbor. Me). C2D (H-t'. class II defi-
cient) mice were purchased from GenPharm International (Moun-
lain View. Calif). Onhotopic liver transplantation was performed 
. as described previously.J Abdominal heart transplantation was 
~;' carried out as described elsewhere.' Total cessation of palpable 
contraction of the heart graft was defined as rejection. Allosensi-
tization by skin grafting was done 14 to 21 days prior to heart or 
liver transplantation. by implanting a full-thickness tail skin graft 
on the dorsal side of the reciplcnt trunk. 
Mixed Lymphocyte Reaction (MLR) 
Equal numbers (2 x lOS) of responder and y-irradiated stimulator 
apleeo cells were cultured at 37°C in 5% CO~ in air and pulsed with 
1 /loCi of [JH)TdR for the last 18 hours of a 4-day culture period. 
The cells were harvested onto glass fiber filters and [3H)TdR 
Uptake was measured by liquid scintillation counting. Results were 
Clpressed as mean counts per minute (cpm) :: 1 SD. 
Lymphocyte-Mediated Cytotoxicity Assay 
Freshly isolated spleen cells were uscd as effectors. The EL4 (H·t') 
lymphoma cell line (ATCC. Rockville. Md) or Con A-activated 
810 splc~n cells were used as targets. The PSIS (H-?') tumor cell 
line or Con A-activated BALB/c~ spleen cells were used as third-
party target controls. The target cells were labeled with Na~ siCrO. 
(NEN. Boston. Mass). washed. and plated at 4 x \OJ cells per 200 
lAUwell at different Err ratios. Killing bv CYtotoxic T celis was 
quantitated by determining the percent~sp~cifi'c 51Cr release over a 
4-hour period. 
Antibody-Dependent Cellular CytotOXIcity (ADCC) 
Antibody titers were measured by modification of method de· 
scribed previouslv.' Briefly. seriallv diluted and decomplemented 
sera were Incubated with target cells (5 x l(5) in microtller plates 
for I hour. The cells were then washed and incubated for 30 
minutes with 100 p.L of baby rabbit complement. At the end of this 
incubation the cells were washed and incubated for an additional :1 
hours in HBSS supplemented with 20 p.L of MIT (Sigma Chemical 
Co. St Louis. Mo). Dimethylsulfoxide (150 p.L) was then added to 
each well. and the optical density was measured using a kinetiC 
microplate reader (Molecular Dcviccs. Menlo Park. Calif). 
RESULTS 
Skin graft-induced sensitization was tested in a fully allo-
geneic BIO -+ C3H liver transplantation model. As previ-
ously reported. B 10 liver allografts were spontaneously 
accepted and survived> 100 days in C3H recipients without 
any immunosuppressive therapy." However. after skin pre-
sensitization. the liver grafts were uniformly rejected in 4 to 
5 days. Kinetic studies demonstrated that donor skin grafts 
took at least 2 weeks to fully sensitize the recipients. and 
sensitization status was stable for up to 3 months. 
As shown in Table I. B10 heart or liver grafts. when 
transplanted into C3H recipients that had received a skin 
graft from B10. B6. or C2D mice 14 to 21 days earlier. were 
rejected in an accelerated fashion: however. this phenom-
enon was not observed in recipients that had been presen-
sitized with either b2m. BlO.BR. or BALB/c skin grafts. 
These results suggest that a skin graft expressing donor-
specific MHC class II antigens alone and/or donor specific 
non-MHC-histocompatibility antigens (non-MHC-HA) is 
incapable of sensitizing the recipient sufficiently to induce 
accelerated rejection of a subsequently transplanted whole 
organ. On the other hand. skin grafts expressing only donor 
MHC class I antigens were able to induce significant 
sensitization in vivo. as evidenced by the accelerated rejec-
tion of the subsequently transplanted heart or liver al-
lografts. 
The immune status of the skin-sensitized C3H mice was 
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Table 1. Survival of 810 Heart or Uver Allografts In Skln-Preaensitized C3H Recipients 
SUl'VIVal (MSn (days) 
Skin 
donor Sensitization loci Heart l.iVef 
B. 8. 8. 8. 9 (8) 35. >100, >100, >100, >100 (>100) 
810 MHC. non-MHC-HA 4. 4, 5. 5. 5 (5) 4, 4, 4, 4, 5 (4) 
86 MHC 3. 3, 4. 4, 5 (4) 4. 5. 5. 5. 8 (5) 
b2m 
" 
7, 7, 7, 8. B. 9 (7. 5) 20.35, >100. >100, >100, >100 (>1001 
C2D 3. 3, 4. 4, 4 (4) 3. 4, 4. 4. 4 (4) 
810.BR Non-MHC-HA 6, 7,7,7. 7.8 (7) 21.28, >100. >100, >100, >100 (>100) 
8ALB/c Third-party B, 5, 9. 9. 9, 9 (9) 15.51. >100, >100. >100, >100 (>100) 
tested in vitro MLR. CI'L. and ADCC assavs, An elevated 
level of H-i'-specific cytotoxicity was detected in fresh 
splenocytes isolated from C3H recipients that had received 
skin grafts from either B1O. B6. or C2D mice. but not from 
b2m, BlO.BR. or BALB/c donors. Furthennore. this ele-
vated donor-specific cytotoxicity correlated well with the in 
vivo observations in which accelerated rejection of a subse-
quently transplanted BlO heart or liver allograft was ob-
served. MLR and ADCC assays did not correlate with these 
in vivo findings, although b2m skin grafts induced a similar 
level of donor-specific ADCC in response to skin allografts 
from C2D mice (Table 1). 
DISCUSSION 
It has been demonstrated that presensitization with fully 
disparate donor skin grafts can lead to accelerated rejection 
of a subsequently transplanted heart or liver allograft. The 
sensitizing antigens appear to be restricted to MHC, since 
BlO.BR skin (which shares the same non-MHC-HA with 
B1O) does not lead to accelerated rejection of either B10 
heart or liver grafts. Within the MHC loci, mismatched 
class I antigens appear to be crucial in sensitizing the 
recipients leading to accelerated rejection of heart and liver 
grafts. whereas class II antigens alone are inefficient in 
generating sufficient sensitization to cause subsequent ac-
celerated rejection. 
It has long been debated whether MHC class I and class 
II antigens play different roles in the immune response to 
allografts.7 In the present study, presensitization by C2D 
skin grafts (MHC class II deficient) led to generation of 
CI'L. while exposure to b2m skin (class I deficient) did not. 
This correlated with the pattern of rejection seen in a 
subsequently transplanted vascularized whole organ. These 
results confirm previous findings that the accelerated ("sec-
ond set") rejection is caused primarily by presensitized 
cytotoxic T cellss in contrast to the primary ("first set") 
rejection which is initiated mainly by the donor MHC class 
II antigens which are known to stimulate helper T cells. 'J 
Furthermore, pre sensitization with b2m and C2D skin 
grafts induced a similar level of donor-specific cytotoxic 
antibody response: however. sensitization with class I-deli-
cient skin grafts failed to induce accelerated rejection of the 
subsequently transplanted whole organ. This suggests that 
the presence of donor-specific cytotoxic antibodies does not 
correlate with accelerated rejection. In fact. the presence 01 
circulating donor-specific MHC class II antibodies hav\: 
been shown to be unlikely mediators of accelerated or 
hyperacute rejection and. in some circumstances. they have 
been documented to prolong allograft survival. IU It is 
interesting to note that, in clinical histocompatibility test-
ing, the presence of donor-specific class II antibody is not 
considered a contraindication for transplantation. 
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